Review
Open access
Aug 2026
Treat-to-target management in inflammatory bowel disease (IBD) combines symptoms, fecal and serum biomarkers, endoscopy, histology, and cross-sectional imaging, but these measures frequently diverge. Discordance may reflect analytical variation, timing, disease location, phenotype, comorbidity, or partially non-overlap...
Lovre Martinović, Roko Šantić, M. Kumrić et al.
· Biomedicines · 0 citations